Valuation: Alvotech

Market Cap 1.63B 1.46B 1.35B 1.22B 2.29B 155B 2.32B 16.23B 6.42B 81.3B 6.13B 6B 256B P/E 2026 *
109x
P/E 2027 * 15.3x
Enterprise Value 2.71B 2.42B 2.24B 2.03B 3.79B 257B 3.85B 26.9B 10.65B 135B 10.17B 9.95B 425B EV / Sales 2026 *
4.15x
EV / Sales 2027 * 3.42x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day+0.20%
1 week+2.60%
Current month-11.55%
1 month-11.70%
3 months+61.32%
6 months+51.78%
1 week 4.56
Extreme 4.565
5.45
1 month 4.56
Extreme 4.565
6.53
Current year 2.94
Extreme 2.94
6.53
1 year 2.94
Extreme 2.94
8.5
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 2026-02-28
Director of Finance/CFO 48 2025-07-09
Chief Tech/Sci/R&D Officer - 2022-12-31
Director TitleAgeSince
Chairman 57 2018-12-31
Director/Board Member 64 2018-12-31
Director/Board Member 58 2018-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/1/26 Free

Chief Executive Officer

117,271 0.0355%
4/1/26 Sell

Founder

318,000 0.0963%
4/1/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%+2.60%-37.06%-41.70% 1.63B
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.27%+1.83%+40.85%+137.62% 38.47B
Weighted average by Cap. +0.39%+2.70%+47.21%+157.72%

Financials

2026 *2027 *
Net sales 653M 583M 538M 488M 913M 61.96B 928M 6.48B 2.57B 32.46B 2.45B 2.4B 102B 786M 702M 648M 588M 1.1B 74.61B 1.12B 7.8B 3.09B 39.09B 2.95B 2.89B 123B
Net income 2.25M 2.01M 1.85M 1.68M 3.14M 213M 3.19M 22.3M 8.83M 112M 8.43M 8.25M 352M 80.1M 71.53M 66.08M 59.88M 112M 7.6B 114M 795M 315M 3.98B 301M 294M 12.56B
Net Debt 1.08B 960M 887M 804M 1.5B 102B 1.53B 10.68B 4.23B 53.49B 4.04B 3.95B 169B 1.06B 943M 871M 789M 1.48B 100B 1.5B 10.48B 4.15B 52.52B 3.96B 3.88B 166B
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
26-10-23 $4.580 -4.38% 666,200
26-10-22 $4.790 -6.63% 926,997
26-10-21 $5.130 +0.20% 480,527
26-10-20 $5.120 +1.79% 1,302,515
26-10-19 $5.030 +0.60% 907,729
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.580USD
Average target price
7.200USD
Spread / Average Target
+57.21%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech
  1. Stock Market
  2. Stocks
  3. ALVO Stock